PainReform (PRFX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PainReform Ltd., a pharmaceutical company, has presented its unaudited condensed financial statements for the first half of 2024, showing a significant decrease in total assets from $9,930,000 at the end of 2023 to $3,107,000 as of June 30, 2024. The report highlights a sharp decline in cash and cash equivalents alongside an increase in total current liabilities, indicating potential financial challenges ahead for the firm.
For further insights into PRFX stock, check out TipRanks’ Stock Analysis page.